Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. (February 2017) - Hong, D.S.; Dowlati, A.; Burris, H.A.; Lee, J.J.; Brose, M.S.; Farago, A.F.; Bauer, T.M.; Taylor, M.; Shaw, A.T.; Smith, S.; Nanda, N.; Cruikshank, S.; et al.